To validate our findings, we analyzed the splicing landscape and expression profiles of key splicing machinery genes, including SRSF2, U2AF1, and ZRSR2, which are known to be frequently mutated in hematological malignancies. This evidence concerns the gene SRSF2 and hematologic disorder.